2-chloro-6,7-dimethoxy-N,N-dimethylquinazolin-4-amine | 494203-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-6,7-dimethoxy-N,N-dimethylquinazolin-4-amine
• CAS: 494203-98-4
• 化学式: C₁₂H₁₄ClN₃O₂
• mdl: MFCD01415943
• 分子量: 267.715
• InChiKey: ZAQWZDUIJCWWMG-UHFFFAOYSA-N

物化性质

• 沸点：
  343.7±42.0 °C(predicted)
• 密度：
  1.287±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  47.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-chloro-6,7-dimethoxy-N,N-dimethylquinazolin-4-amine 、 4-吡咯烷-1-基哌啶 以 正丁醇 为溶剂， 以18 mg的产率得到6,7-dimethoxy-N,N-dimethyl-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine
  参考文献：
  名称：

  Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines

  摘要：

  A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.036
• 作为产物：
  描述：

  2,4-二氯-6,7-二甲氧基喹唑啉 、 二甲胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 2-chloro-6,7-dimethoxy-N,N-dimethylquinazolin-4-amine
  参考文献：
  名称：

  Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines

  摘要：

  A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.036

文献信息

• QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100125078A1

  公开（公告）日：2010-05-20

  The present invention relates to a compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein and to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下式I的化合物 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 和n如本文所定义，并且涉及其药用活性盐，外消旋混合物，对映体，光学异构体或其互变异构体形式。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• US8318749B2
  申请人：——

  公开号：US8318749B2

  公开（公告）日：2012-11-27
• [EN] NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ DESTINÉ À AMÉLIORER LE SOMMEIL OU SON UTILISATION<br/>[KO] 수면 개선용 신규 화합물 내지 이의 용도
  申请人：[en]AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION;[ko]아주대학교산학협력단

  公开号：WO2023121429A1

  公开（公告）日：2023-06-29

  본 발명은 수면 개선 효과를 제공할 수 있는 신규한 화합물 내지 이의 용도에 대한 것이며, 일부 화합물들은 아데노신 수용체의 효현제 활성을 가지고 있다. 본 발명의 신규 화합물은 입면시간을 단축시키고 총 수면시간을 증가시킬 수 있어 수면장애 예방 또는 치료용 약학적 조성물, 수면 장애 예방 또는 개선용 건강기능식품 조성물, 수면 개선용 조성물, 수면 보조제 내지 수면장애 치료 방법에 효과적으로 사용될 수 있다.
• Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines
  作者：Kazuhiro Yokoyama、Noriko Ishikawa、Susumu Igarashi、Noriyuki Kawano、Kazuyuki Hattori、Takahiro Miyazaki、Shin-ichi Ogino、Yuzo Matsumoto、Makoto Takeuchi、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2008.05.036

  日期：2008.7

  A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.